All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

September 30th 2025

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer

September 30th 2025

While clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.

AI Offers Multitude of Benefits in Community Practice, But Barriers to Implementation Remain

September 29th 2025

Kashyap Patel MD, ABIM, BCMAS, discusses the present challenges with integrating AI tools into community practice.

Orphan Drug Designation Sought for Crofelemer to Manage Treatment-Related Diarrhea in Breast Cancer With Brain Metastases

September 29th 2025

Crofelemer may receive ODD for diarrhea treatment in patients with breast cancer and brain metastases receiving targeted therapy with/without chemotherapy.

Predictors of cGVHD Outcomes Remain Elusive in Pediatric Hematologic Malignancies

September 29th 2025

Acute GVHD was shown to be a risk factor for chronic GVHD, but factors such as organ involvement showed no correlation with long-term outcomes.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

FDA Clears Guardant360 CDx as Companion Diagnostic for Imlunestrant in ESR1-Mutated Breast Cancer

September 29th 2025

The Guardant360 CDx liquid biopsy test has been approved to identify patients with ESR1-mutated breast cancer who are eligible to receive imlunestrant.

T-DXd Yields iDFS Improvement vs T-DM1 in High-Risk HER2+ Early Breast Cancer After Neoadjuvant Therapy

September 29th 2025

Trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival vs trastuzumab emtansine in HER2-positive early breast cancer.

Mayo Clinic Experts Present Key Radiation Oncology Findings at ASTRO

September 29th 2025

Recognizing the Rapidly Changing World of Surgical Oncology

September 29th 2025

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

AI-Based Tools Offer Clinical Decision-Making Support in Community Practice

September 29th 2025

Jim Chen, MD, discusses how artificial intelligence can aid community oncologists in providing optimal care.

From Overload to Insight: Why AI Is Becoming an Essential Partner in Oncology

September 28th 2025

Brian P. Mulherin, MD, discusses how artificial intelligence is helping shape smarter cancer care.

AI Clinical Decision Support Systems Act as “Copilots” to Enhance Patient Care

September 28th 2025

AI-powered clinical decision support systems can help oncologists manage rising information demands without forfeiting autonomy in care delivery.

Five Under 5: Top Oncology Videos for the Week of 9/21

September 28th 2025

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

Simplifying Care Navigation in Oncology: A Painless Path to Better Support

September 28th 2025

Lalan Wilfong, MD, discusses the patient- and provider-facing implications that may result from renewed focus on improving care navigation in oncology.

Flora Charts the Future of AI in Community Cancer Care

September 27th 2025

Doug Flora, MD, FACC, LSSBB, explains how AI is transforming cancer care, urging oncologists to engage and guide its responsible use.

The OncFive: Top Oncology Articles for the Week of 9/21

September 27th 2025

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Poll Results Spotlight Key Lung Cancer Abstracts Driving Anticipation Ahead of ESMO 2025

September 26th 2025

OncLive social media polls reveal which lung cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

ASCENT-GYN-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer

September 26th 2025

Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.

Poll Results Spotlight Key GU Cancer Abstracts Driving Anticipation Ahead of ESMO 2025

September 26th 2025

OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.